Last reviewed 2026-04-23 · How we verify

phase II

This drug works by inhibiting the activity of a specific enzyme.

This drug works by inhibiting the activity of a specific enzyme. Used for Type 2 diabetes, Heart failure.

At a glance

Mechanism of action

By inhibiting this enzyme, the drug reduces the production of a certain substance in the body, which in turn helps to alleviate symptoms of the target disease. This mechanism of action is thought to be responsible for the therapeutic effects of the drug.

Approved indications

• Type 2 diabetes
• Heart failure

Common side effects

• Nausea
• Diarrhea
• Vomiting
• Hypotension
• Increased urination

Key clinical trials

• A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (PHASE2)
• Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
• Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
• An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis (PHASE2)
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (PHASE2)
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
• A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.